Pallas Health Review: Sermorelin Price, Billing and Pharmacy Network

The short version

Pallas Health currently advertises sermorelin at $139 for the first month, then $179 every four weeks, with an annual plan at a $119/month average.¹ These are different payment arrangements. Four weeks is not a calendar month, and an annual average does not establish a monthly payment.

Pallas names a clinician and pharmacy network in its clinical disclosures. Those details offer a practical starting point for verification, rather than a guarantee about who will treat you or fill your order. We may earn a commission through our links; our disclosure explains that relationship.

Price, renewal and cancellation

The introductory $139 rate is followed by $179 every four weeks. Thirteen four-week billing periods fit into 52 weeks, so thirteen recurring charges would total $2,327, before any introductory-period adjustment. The annual $119/month average needs its own upfront charge, prescription supply and renewal terms confirmed.

The product describes clinician care, check-ins and care-team messaging without a separate membership fee. Confirm the actual medication, shipping and total in the order terms. An intake does not guarantee clinical approval or a prescription.

The plan renews until canceled. Canceling future renewals does not necessarily refund a current prescription. The homepage and Terms present different effective dates for refund language; obtain written confirmation of the policy governing your order. Current Terms describe prescription issuance as a final-order cutoff.⁶

What it discloses, and why that is the story

Most of the sellers we track will not tell you who compounds the drug. Pallas publishes a compliance page — /clinical, dated on its face — that answers the questions a careful buyer actually has:

• •Six partner pharmacies, named, with phone numbers and domains: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills Pharmacy. It states that the pharmacy used depends on the medication, your shipping state and current capacity, and that state pharmacy license numbers are disclosed on request.
• •A correct explanation of compounding classes — 503A pharmacies licensed and inspected by state boards, 503B outsourcing facilities registered with and inspected by the FDA under cGMP. Most sites in this category either skip this or blur "FDA-registered" into "FDA-approved." Pallas does neither.
• •A named physician you can check: Dr Ana Lisa Carr, MD, board-certified in family, obesity and addiction medicine, listed as advising physician with NPI 1689841744 and an invitation to verify it in the NPPES registry.
• •A named corporate structure: the platform is operated by Brentmoor, Inc., which states that it does not employ medical providers, does not practice medicine and does not direct clinical decisions. Clinical care is delivered by Lion MD, a nationwide clinician network, through CareValidate, the clinical-operations platform that verifies licensure and coordinates dispensing.
• •Fifty states and the District of Columbia, listed individually.
• •A promise that you are given your treating clinician's name and license information before any prescription is issued, and that refills are not automatic — each renewal involves a clinician reviewing progress and tolerability.

There is one qualifier that matters, and it is the reason this section is praise rather than a recommendation on its own. That bench is shared. The same six pharmacies and the same Lion MD clinician network appear, in near-identical wording, on other brands running the CareValidate platform — Dr Carr is the same advising physician Synergy Rx names, and Care Bare Rx publishes the same pharmacy list. So this is genuine disclosure about the platform your prescription passes through, not independent evidence about Pallas specifically. Of the three, Pallas writes it up best.

The other qualifier is placement: none of this is on the sermorelin page. A reader who lands on the product, reads the price and clicks buy never meets it. It sits behind a footer link.

What it does not publish

No dose, strength or vial size. The page says "subcutaneous injection with clinician-personalized dosing" and leaves it there, so you cannot compare cost per milligram against a provider that does publish one.

No named pharmacy for your order in advance — six are named, but which one fills yours depends on your state and on capacity, and you find out later.

No FAQ or About page. Both /faq and /about return nothing; the compliance page carries what would normally live there.

To its credit, the sermorelin page does list contraindications in plain language — pregnancy or breastfeeding, active cancer, pituitary disease, untreated hypothyroidism, uncontrolled diabetes, heart failure — and answers "Is compounded sermorelin FDA-approved?" with a flat "No." That is more candor than most of this market manages, and it is the right answer⁴.

What the evidence can support

Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone. It does not supply growth hormone; it prompts your own pituitary to release more of it², which is why it is dosed at night and why the best-supported effects are on sleep and the GH/IGF-1 axis rather than on the mirror. Nightly GHRH(1-29) raised GH without increasing IGF-1 in healthy older men in an uncontrolled six-week study of eleven men³; the wider literature on augmenting growth hormone in healthy adults finds small body-composition changes, no functional gain and a real side-effect rate⁵. Our evidence review grades each claim.

Our assessment

Pallas provides specific network disclosures and both introductory and recurring pricing. Confirm the assigned clinician and dispensing pharmacy, then read the renewal period carefully. The four-week charge and annual average are different commitments. Compare the same payment period and formulation on our price comparison, and clarify refund terms before prepaying.